



The Truth in Small Doses
Why We're Losing the War on Cancer-and How to Win It
-
- $1.99
-
- $1.99
Publisher Description
A “brilliant” (Fortune), eye-opening history of the war on cancer, The Truth in Small Doses asks why we are losing this essential fight and charts a path forward.
Over the past half century, deaths from heart disease, stroke, and so many other killers have fallen dramatically. But cancer continues to kill with abandon. In 2013, despite a four-decade “war” against the disease that has cost hundreds of billions of dollars, more than 1.6 million Americans will be diagnosed with cancer and nearly six hundred thousand will die from it.
A decade ago, Clifton Leaf, a celebrated journalist and a cancer survivor himself, began to investigate why we had made such limited progress fighting this terrifying disease. The result is a gripping narrative that reveals why the public’s immense investment in research has been badly misspent, why scientists seldom collaborate and share their data, why new drugs are so expensive yet routinely fail, and why our best hope for progress—brilliant young scientists—are now abandoning the search for a cure. “Through flowing prose Leaf delivers, alongside facts and data, stories on personalities involved in research, the fascinating process of solving an unusual and highly deadly cancer in Africa, and the heartbreaking realities of cancer treatment in children today. Leaf’s extensively investigated treatise will resonate with researchers and patients frustrated by the bureaucratic woes he delineates. Public policy makers, grant reviewers, and pharmaceutical researchers alike must consider Leaf’s indictment and proposed solutions” (Publishers Weekly). The Truth in Small Doses is that rare tale that will both outrage readers and inspire conversation and change.
PUBLISHERS WEEKLY
Former Fortune editor Leaf dissects years of cancer death rates to reveal the reality of the fight against cancer; in over 40 years, and despite $16 billion per year spent on drug development and other research, there has been little change in individual cancer death rates. Rather than pursuing preemption, which was understood as the answer even in the early 1970s, "ur current system is designed not to solve problems, but to produce studies." Researchers face many difficulties, from obtaining funding or tissue samples to low enrollment for clinical trials. As an observer and a cancer survivor, Leaf proposes that scientists be freed from the stifling research culture by aligning funding with improved goals, simplifying management, and consolidating laboratory capabilities and efforts. Through flowing prose Leaf delivers, alongside facts and data, stories on personalities involved in research, the fascinating process of solving an unusual and highly deadly cancer in Africa, and the heartbreaking realities of cancer treatment in children today. Leaf's extensively investigated treatise will resonate with researchers and patients frustrated by the bureaucratic woes he delineates. Public policy makers, grant reviewers, and pharmaceutical researchers alike must consider Leaf's indictment and proposed solutions.